This study focuses on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a condition that affects the nerves outside the brain and spinal cord, causing weakness, numbness, and tingling in the arms and legs. The study will test a new medication called DNTH103, which is given as an injection, compared to placebo. The purpose is to determine how long it takes for symptoms to return (relapse) after treatment with DNTH103.

The study involves two main parts. In the first part, all participants receive DNTH103 to check if they respond to the treatment. In the second part, participants who showed improvement will be randomly assigned to continue receiving either DNTH103 or placebo. The treatment period lasts several months, during which participants will receive regular injections and undergo various assessments to monitor their condition.

Throughout the study, doctors will measure participants’ muscle strength, ability to perform daily activities, and overall quality of life. They will also monitor for any side effects and check how the medication works in the body. The maximum daily dose of DNTH103 will be 1200 mg, and participants may receive treatment for up to 172 days.